GlassScriptPhysician profile
Fernando A Bolanos Cruz
NPI 1992935951
$1,311.45
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $82.40 · 2020: $550 · 2021: $563 · 2022: $34.43 · 2023: $81.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $81.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $81.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $530.46 | 2019-2023 | Xarelto |
| Vifor Pharma, INC. | $145.51 | 2020-2022 | |
| Janssen Scientific Affairs, LLC | $124.98 | 2021 | |
| Novartis Pharmaceuticals Corporation | $69.87 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $60.19 | 2020-2022 | |
| Paratek Pharmaceuticals, INC. | $48.03 | 2020-2021 | |
| Pharmacosmos Therapeutics INC. | $44.41 | 2020-2021 | |
| Biogen, INC. | $43.69 | 2021 | |
| Pfizer INC. | $35.88 | 2019-2020 | |
| Portola Pharmaceuticals, LLC | $34.90 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $33.07 | 2021 | |
| Merck Sharp & Dohme LLC | $26.09 | 2023 | Dificid, Recarbrio, Zerbaxa |
| Astrazeneca Pharmaceuticals LP | $24.25 | 2023 | Brilinta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.98 | 2021 | |
| Astellas Pharma US INC | $21.58 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $15.00 | 2020 | |
| Philips North America LLC | $14.92 | 2021 | |
| Novo Nordisk INC | $14.64 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fernando Bolanos Cruz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.